Pyxis Oncology Inc(PYXS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:23 PM ET (Korea 10/29 05:23)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.4 | Insider Own | 13.92% | Shs Outstand | 119.6M | Perf Week | 12.5% |
| Market Cap | 0.24B | Forward P/E | - | EPS next Y | 8.7% | Insider Trans | -0.21% | Shs Float | 102.9M | Perf Month | -31.72% |
| Enterprise Value | 0.22B | PEG | - | EPS next Q | -0.28 | Inst Own | 32.91% | Short Float | 4.22% | Perf Quarter | -31.01% |
| Income | -0.09B | P/S | 21.45 | EPS this Y | 5.21% | Inst Trans | 0.32% | Short Ratio | 3.53 | Perf Half Y | 19.28% |
| Sales | 0.01B | P/B | 10.98 | EPS next 5Y | 6.15% | ROA | -99.62% | Short Interest | 4.35M | Perf YTD | 72.17% |
| Book/sh | 0.18 | P/C | 6.87 | EPS past 3/5Y | 29.49% -27.93% | ROE | -179.1% | 52W High | -64.32% ($5.55) | Perf Year | -41.76% |
| Cash/sh | 0.29 | P/FCF | - | Sales past 3/5Y | - | ROIC | -323.25% | 52W Low | 92.23% ($1.03) | Perf 3Y | 26.11% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.7% | Gross Margin | 40.46% | Volatility(W/M) | 6.55% 7.27% | Perf 5Y | -85.11% |
| Dividend TTM | - | EV/Sales | 19.94 | Sales Y/Y TTM | 291.42% | Oper. Margin | -834.44% | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.34 | EPS Q/Q | -33.64% | Profit Margin | -803.83% | RSI (14) | 43.68 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.34 | Sales Q/Q | -100% | SMA20 | 4.18% ($1.9) | Beta | 1.38 | Target Price | $8.67 |
| Payout | - | Debt/Eq | 1.56 | Earnings | 2026/8/13 | SMA50 | -27.01% ($2.71) | Rel Volume | 0.59 | Prev Close | $1.84 |
| Employees | 56 | LT Debt/Eq | 1.4 | EPS/Sales Surpr. | -14.29% -100% | SMA200 | -8.29% ($2.16) | Avg Volume(3M) | 1.23M | Price | $1.98 |
| IPO | 2021/10/8 | Option/Short | Yes/Yes | Trades | 3053 | Volume | 727,024 | Change | 7.61% |
🧬 Fixyx Oncology is a clinical-stage biotech company developing treatments for solid tumors. The company has an antibody-drug conjugate and immuno-oncology pipeline targeting difficult-to-treat solid tumors, including head and neck squamous cell carcinoma, and is headquartered in the US. Backed by multiple venture capital investors, it is focused on generating initial clinical data.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded less than usual. That is 59% of its average volume.
PYXS has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +5.2% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,145. Peers typically go for $1,089.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -85.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 32.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #287 of 594 in the industry
Based on market cap of $237M.
VNDA#285 Vanda Pharmaceuticals Inc $242M PER - 
ACIU#286 AC Immune SA $241M PER - PYXS#287 Pyxis Oncology Inc $237M PER - 
KROS#288 Keros Therapeutics Inc $230M PER - 
CAMP#289 CAMP4 Therapeutics Corp $229M PER - 
FAQ
What kind of company is PYXS?
PYXS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PYXS?
The market cap of PYXS is approximately $237M, ranking 3,888 within its sector.
What is the 52-week high and low for PYXS?
PYXS has recorded a 52-week high of $5.55 and a low of $1.03.
